Mounting evidence has illustrated the vital roles of long non-coding RNAs (lncRNAs in gastric cancer (GC). Nevertheless, the majority of their roles and mechanisms in GC are still largely unknown. In this study, we investigate the roles of lncRNA SLC25A5-AS1 on tumourigenesis and explore its potential mechanisms in GC. The results showed that the expressions of SLC25A5-AS1 in GC were significantly lower than that of adjacent normal tissues, which were significantly associated with tumour size, TNM stage and lymph node metastasis. Moreover, SLC25A5-AS1 could inhibit GC cell proliferation, induce G1/G1 cell cycle arrest and cell apoptosis in vitro, as well as GC growth in vivo. Dual-luciferase reporter assay confirmed the direct interaction between SLC25A5-AS1 and miR-19a-3p, rescue experiment showed that co-transfection miR-19a-3p mimics and pcDNA-SLC25A5-AS1 could partially restore the ability of GC cell proliferation and the inhibition of cell apoptosis. The mechanism analyses further found that SLC25A5-AS1 might act as a competing endogenous RNAs (ceRNA), which was involved in the derepression of PTEN expression, a target gene of miR-19a-3p, and regulate malignant phenotype via PI3K/AKT signalling pathway in GC. Taken together, this study indicated that SLC25A5-AS1 was down-regulated in GC and functioned as a suppressor in the progression of GC. Moreover, it could act as a ceRNA to regulate cellular behaviours via miR-19a-3p/PTEN/PI3K/AKT signalling pathway. Thus, SLC25A5-AS1 might be served as a potential target for cancer therapeutics in GC.
| INTRODUC TI ON
Gastric cancer (GC) is one of the most common types of digestive system tumours, which has been steadily decreasing worldwide recently. But it is still the most important leading cause of cancer mortality in the East Asia.
1 Most patients with GC are in Chinese eastern cities, and the morbidity of GC is twice as common in women as in men. 2 In China, the incidence of GC is the third highest among malignant tumours in males and the fourth in females. 3 In Japan, benefit from early diagnosis, the survival rate for GC is as high as 52%, while 20%-25% in China. 4 The earlier the GC is identified, the better the prospect of a cure, but because of lack of identifying novel diagnostic biomarkers, the majority of GC patients is diagnosed at a late stage. 5 Therefore, it is critical to find novel diagnostic biomarkers and effective therapeutics for GC patients.
Long non-coding RNAs (lncRNAs) are a class of RNA transcripts which are longer than 200 nucleotides in length and lack of proteincoding ability. 6, 7 Generally, they have fewer exons than mRNA and lack extended open reading frames (ORF). 8 LncRNAs can participate in a series of biological processes, including genomic imprinting, chromosome modification, transcription activation, cell cycle regulation, splicing translation and epigenetic regulation, etc. 9 Since HOTAIR was discovered, humans had been increasingly concerned about the lncRNAs that was initially thought to be 'Genomic Junk'."
Increasing evidence has revealed that dysregulated expression of lncRNAs played critical roles in various disease pathogenesis, including proliferation, invasion, migration and prognosis of malignant tumours, including GC. 10 However, the dysregulated lncRNAs and their function mechanisms in GC have not been extensively studied.
In order to reveal the potential tumourigenesis-related lncRNAs in the progression of GC, we used microarray analysis to explore dysregulated lncRNAs in GC and found that NR_028443.1 (SLC25A5-AS1), as a novel lncRNA, had not been reported previously. In this study, we mainly aimed to investigate the expression pattern and functions of lncRNA SLC25A5-AS1 in GC and explore the possible mechanisms of SLC25A5-AS1 in GC. We reported a lower expression of SLC25A5-AS1 in GC, and several biological experiments were performed to verify SLC25A5-AS1 could suppress GC cell proliferation, cell cycle progression and promote apoptosis by acting as competing endogenous RNAs (ceRNA) in interaction with miR-19a-3p through PTEN/PI3K/AKT signalling pathway.
| ME THODS AND MATERIAL S

| Patients and tissue samples
A total of 56 GC tissues and their pair-matched adjacent normal tissues were obtained from patients who were diagnosed with GC at the Affiliated Hospital of Nantong University from January 2015 to
May 2017. The written informed consents were obtained from all the subjects and this study was approved by the Ethics Committee of Affiliated Hospital of Nantong University (Nantong, Jiangsu, China). No patients had received chemotherapy or pre-operative radiotherapy. All the samples were immediately infiltrated in l mL RNA latter (Qiagen, Germany) after surgical resection and stored at −80°C until for RNA isolation. The clinical parameters of GC patients in this study were presented in Table 1 .
| Cell culture
The human normal gastric epithelial cell line (GES-1) and human GC cell lines (AGS, SGC-7901, BGC-823, and HGC-27) were purchased from the Cell Resources Center of the Chinese Academy of Science. Cells were cultured in the RPMI1640 (Corning, USA) complete medium and incubated at 37°C in a humidified incubator with 5% CO 2 . The composition of the complete medium is RPMI1640 medium added with 10% foetal bovine serum (Gibco, NY, USA).
| Microarray analysis
The Agilent Human lncRNA Microrrays V5 (4*180K, design ID: 076500) were used to analyse lncRNA expression profiles in eight samples (four GC tissues and four paired corresponding non-tumourous tissues). Total RNA was quantified by the NanoDrop ND-2000 (Thermo Scientific) and the RNA integrity was assessed using Agilent
Bioanalyzer 2100 (Agilent Technologies). Briefly, total RNA was transcribed to double strand cDNA, then synthesized into cRNA and The bold treatment indicated a significant result featured by P < 0.05.
labelled with Cyanine-3-CTP. The labelled cRNAs were hybridized onto the microarray. After washing, the arrays were scanned by the Agilent Scanner G2505C (Agilent Technologies). GeneSpring (version 13.1, Agilent Technologies) was employed to analyse the raw data. Differentially expressed genes or lncRNAs were then identified through fold change as well as P value calculated with t-test.
The threshold set for up-and down-regulated lncRNAs was a fold change 2.0 and P ≤ 0.05. Finally, hierarchical clustering was performed to display the distinguishable genes' expression pattern among samples.
| RNA extraction and quantitative real-time polymerase chain reaction (qRT-PCR)
Total RNA was extracted using RNA extraction Kit (Thermo The expression levels of lncRNA, miRNA or mRNA was normalized to the expression of 18S rRNA or U6 using the 2 -ΔΔct method.
Primers used for amplifying specific genes were purchased from GenePharma (Shanghai, China) and the sequences were as follows, 
| Proliferation assay
| Luciferase reporter assays
Cells were seeded at a concentration of 5×10 4 
| Western blot analysis
Total protein was extracted from GC cells after transfection for were detected using Chemiluminescence imaging system (BIO-RAD, USA) with GAPDH used as a control. 
| Tumour formation in nude mice
| Immunohistochemistry
The tumours were fixed in 4% paraformaldehyde solution at 4°C
for 48 hours, then embedded in paraffin and sectioned into 4 μm thick. Slides were deparaffinized through a series of xylene and graded alcohols. For antigen retrieval, slides were heated in citrate buffer (pH 6.0) in sub-boiling temperature for 10 minutes.
Then endogenous peroxidase activity was blocked by 3% H 2 O 2 for 15 minutes, and then the slides were incubated with primary antibody overnight at 4°C. Next day, the secondary antibody (Gene Tech, Shanghai, China) was applied for 30 minutes at room temperature. Following Diaminobenzidine (DAB) staining for appropriate time, haematoxylin staining was performed. The antibodies against Ki-67 (1:1000) were purchased from CST (USA).
| Statistical analysis
Graphad Prism 6 was used for the statistical analysis. The significance of differences between groups was estimated by Student's t-test and multiple groups were estimated with one-way ANOVA.
Spearman's correlation analyses were analysed between SLC25A5-AS1and PTEN or miR-19a-3p expression levels in GC tissues.
P < 0.05 was considered statistically significant. Each experiment was conducted in triplicate.
| RE SULTS
| SLC25A5-AS1 was down-regulated in GC tissues and associated with tumour progression
Firstly, lncRNA microarray was used to analyse abnormal expressed lncRNAs in four paired GC tissues and corresponding F I G U R E 1 Expression of SLC25A5-AS1 in GC tissues and its association with clinicopathological characteristics. A, Hierarchical clustering analysis of the lncRNAs that were differentially expressed (fold change >2 or <−2, P < 0.05) between GC tissues (Tumour) and paired non-tumour tissues (NonTumour). B, SLC25A5-AS1 was detected in 56 pairs of GC tissues by qRT-PCR. The level of SLC25A5-AS1 was significantly decreased in GC tissues, as compared with matched adjacent normal tissues, P < 0.0001. C, SLC25A5-AS1 expression was significantly down-regulated in 80.4% (45 of 56 paired). The results were normalized to adjacent normal tissues and shown as log2 (2 -ΔΔCt ). D, SLC25A5-AS1 expression was significantly decreased in patients with advanced tumour size, **P < 0.01. E, ROC curve for prediction of GC based on SLC25A5-AS1 expression level, the AUC was 0.7699 (95% CI 0.6831-0.8567) adjacent normal tissues. We identified 87 up-regulated lncRNAs and 117 down-regulated lncRNAs that were filtered by the criteria of fold change >2 and P < 0.05 between cancer and adjacent normal specimens, hierarchical clustering analysis showed a clear distinction on most significantly dysregulated expression of lncRNAs in cancer as depicted in the heat map ( Figure 1A ). Among them, we selected an anti-sense lncRNA, named SLC25A5-AS1, which was down-regulated in GC. In order to further assess whether SLC25A5-AS1 was dysregulated in GC, we performed qRT-PCR to analyse the expression of SLC25A5-AS1 in 56 GC tissues. We found that the level of SLC25A5-AS1 was significantly decreased in GC tissues, as compared with matched adjacent normal tissues, P < 0.0001 ( Figure 1B ). SLC25A5-AS1 expression was down-regulated in 80.4% (45 of 56 paired) GC tissues ( Figure 1C ).
Furthermore, we investigated whether its expression was associated with the patients' clinicopathological characteristics. As shown in Figure 1D , SLC25A5-AS1 level was associated with tumour size (P < 0.01), and lymph node metastasis (P < 0.05) and TNM stage as well (P < 0.05, Table 1 ), but not associated with sex, ages or histological differentiation, all P > 0.05. Additionally, the receiver operating characteristic (ROC) curve was constructed to assess diagnostic value of SLC25A5-AS1 level. The results
showed that the area under the ROC curve of SLC25A5-AS1 was 0.7699 (95% CI 0.6831-0.8567), indicating SLC25A5-AS1 might be a good diagnostic marker for GC ( Figure 1E ). These data suggested that SLC25A5-AS1 might play an important role in tumour development and metastasis in GC. Figure 3D ). In addition, we also detected cycle-associated proteins (cyclinD1, P27) and apoptosis-associated proteins (BCL-2, BAX) by Western blot analysis, the results revealed that the protein level of cyclinD1 and BCL-2 was increased while P27 and BAX was decreased in SLC25A5-AS1-knockdown HGC-27 cells, while in SLC25A5-AS1-overexpressed BGC-823 and SGC-7901 cells, as expected, we obtained opposite results ( Figure 3E ).
| SLC25A5-
| SLC25A5-AS1 regulates GC growth in vivo
According to the findings of SLC25A5-AS1 inhibiting GC cell proliferation, cell cycle and apoptosis in vitro, we next examined the effect of SLC25A5-AS1 on GC growth in vivo. We firstly established a nude mice model by subcutaneously injecting the SGC7901 cells into the ventral side. Two weeks after the subcutaneous injection, we found that the tumours formed in the pcDNA-SLC25A5-AS1 transfected group had smaller tumour size than those in vector control group ( Figure 4A,B) . Moreover, the tumours formed in the pcDNA-SLC25A5-AS1 transfected group had lighter weight than those in vector control group ( Figure 4C ). These results were further confirmed by immunohistochemical staining and HE staining of tumour tissues. The results indicated that lower expression of Ki-67 was observed in pcDNA-SLC25A5-AS1-treated group ( Figure 4D ).
Taken together, these vivo data demonstrated that SLC25A5-AS1 might act as an anti-oncogene which could suppress GC cell proliferation.
| SLC25A5-AS1 functions as a ceRNA directly interacted with miR-19a-3p
Increasing showed that as compared with pcDNA-SLC25A5-AS1+ miR-NC group, pcDNA-SLC25A5-AS1+miR-19a-3p group could reverse the reduced cell proliferation, the increased cell apoptosis and the arrest of G0/G1 cell cycle (Figure 6A-D) . Overall, these results revealed that the carcinostatic effects of SLC25A5-AS1 were at least partly through inhibiting miR-19a-3p.
| SLC25A5-AS1 inhibits cell growth and promotes apoptosis via miR-19a-3p -PTEN/PI3K/AKT signalling pathway
To find the target of miR-19a-3p, we used Targetscan 
| D ISCUSS I ON
The development of GC is a multi-stage and multi-factorial process, which is one of the main fatal tumours that threaten our health in China. 3, 16 For a long time, many tumour researchers have paid more attention to multiple genetic and epigenetic alterations on coding genes. 17, 18 With the development of microarray and RNA sequencing technology, 19 more and more non-coding RNAs (ncRNAs) were characterized. According to the positional relationship between lncRNA and the protein-coding genes, they can be divided into sense lncRNA, anti-sense lncRNA, bidirectional lncRNA, intergenic lncRNA and intronic lncRNA. [20] [21] [22] Increasing evidence has demonstrated that anti-sense lncRNAs are featured as crucial regulators during tumourigenesis, and play critical roles in tumour proliferation, cell cycle and apoptosis, which maybe act as valuable diagnostic and prognostic biomarkers for cancer. 23 Zhang et al 24 Microarray and RNA-seq are effective tools for high-throughput detection of lncRNA expression, which can simply screen out a large number of genes associated with tumour development. To explore the differential expression of lncRNAs in GC tissues and corresponding adjacent normal tissues, we extracted the total RNA in four paired GC and corresponding adjacent normal tissues and conducted a microarray, the results were verified by qRT-PCR. In our present study, we found that SLC25A5-AS1, an anti-sense lncRNA that located in X chromosome q24, was firstly identified as a dysregulated lncRNA in GC. There was less report about the genes located in X chromosome than those located in other chromosomes. XIST was the first reported tumour-associated gene located in X chromosome. 27 Previous study showed that XIST knockdown could inhibit GC progression and metastasis through modulating the expression of EZH2. 28 It seems that XIST gene is up-regulated in a variety of non-sex-related tumours in both humans and mice. 29 In our present study, we found that SLC25A5-AS1 was significantly decreased in 34 For example, lncRNA GAS5 levels were significantly reduced in prostate cancer, and GAS5 overexpression can inhibit tumour progression in part through its inhibitory effects on the expression and activity of miR-103. 35 Similar reports indicated that CASC2 could function as a ceRNA to modulate miR-181a and promote glioma growth and sensitize glioma cells to TMZ. 36 Ma et al 37 revealed a reciprocal repression between lncRNA GCASPC and miR-17-3p in gallbladder cancer.
The theory of ceRNA considers that lncRNA, mRNA and pseudogene transcription products can be competitive with miRNAs, function as a 'molecular sponge', reduce the number of miRNAs interacting with mRNA, regulate the expression of miRNAs downstream target genes in post-transcriptional level. 38 In our current study, we also found that SLC25A5-AS1 might function as a ceRNA directly interacting with miR-19a-3p by dual-luciferase reporter assay. Furthermore, the effect of pcDNA-SLC25A5-AS1 was partially attenuated the ability of miR-19a-3p mimics on GC cell proliferation indicating that SLC25A5-AS1 may interact with miR-19a-3p to regulate the progress of GC. Previous studies confirmed that miR-19a could act as an oncogene in GC, 39 lung cancer, 40 colon cancer, 41 breast cancer 42 and so on. Moreover, it could regulate the PTEN/AKT signalling pathway in myeloma and 43 breast cancer. 44 In conclusion, our study revealed that SLC25A5-AS1 was downregulated in GC and functioned as a suppressor gene in the progression of GC. Additionally, SLC25A5-AS1 might act as a ceRNA to sponge miR-19a-3p and regulate cellular behaviours via PTEN/PI3K/ AKT signalling pathway in GC. Taken together, our present results indicated that SLC25A5-AS1 might be served as a potential target for cancer therapy in GC.
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